

The Selective Dopamine D₁ Receptor Agonist SK&F 38393: Its Effects on Palatability- and Deprivation-Induced Feeding, and Operant Responding for Food

ILENE N RUSK AND STEVEN J. COOPER¹

School of Psychology, University of Birmingham, Birmingham, B15 2TT, U.K.

Received 3 January 1989

RUSK, I N AND S J COOPER *The selective dopamine D₁ receptor agonist SK&F 38393 Its effects on palatability- and deprivation-induced feeding, and operant responding for food* PHARMACOL BIOCHEM BEHAV 34(1) 17-22, 1989 — A series of experiments investigated the involvement of the dopamine D₁ receptor subtype in relation to feeding responses. The selective D₁ agonists, SK&F 38393 (1 0–20 mg/kg) and SK&F 75760 (5 mg/kg), significantly reduced palatable food consumption in nondeprived rats. The anorectic effect of SK&F 38393 (10 mg/kg) was additive with that of the selective D₂ receptor agonist, N-0437 (0.3 mg/kg). In nondeprived mice, SK&F 38393 had a stereoselective effect to reduce palatable food intake. At a peripherally-selective dose (3.0 mg/kg), the peripheral dopamine D₁ receptor agonist, fenoldopam, had no effect on food intake. At 10 mg/kg, however, it exhibited anorectic properties, although this may have been due to some penetration of the blood-brain barrier. In rats adapted to a food-deprivation schedule, SK&F 38393 (3.0–30 mg/kg) produced significant dose-dependent reductions in consumption of powdered chow and in lever-pressing for food pellets on a FR8 schedule of reinforcement. In rats adapted to a water-deprivation schedule, SK&F 38393 (3.0–30 mg/kg) was substantially less effective in reducing water intake. The results are discussed in terms of a possible selective effect of D₁ agonist activity on feeding behaviour.

Anorexia	Dopamine D ₁ receptor	Fenoldopam	N-0437	SK&F 38393	SK&F 75760	Rats	Mice
----------	----------------------------------	------------	--------	------------	------------	------	------

EVIDENCE indicates that stimulation of centrally-located dopamine receptors can lead to suppression of food. Thus, the dopamine receptor agonists apomorphine (6, 19, 29), 2-di-n-propylamine-4,7-dimethoxyindane, RDS-127 (1), pergolide (15), and the ergot derivatives, bromocriptine, lisuride and lergotril (9) reduce the consumption of standard laboratory diets during restricted access to food. The reductions in food intake are antagonized by a number of dopamine antagonists (18,19), but not by the peripheral dopamine antagonist, domperidone (9,29). Leibowitz and Rossakis have mapped dopamine-sensitive sites in the rat brain, and have shown that the perifornical region of the lateral hypothalamus is most sensitive to the feeding-suppressant effect of dopamine (24). Dopamine antagonists block the dopamine effect (25), while intrahypothalamic injections of sulpiride, a specific D₂ receptor antagonist, elicits feeding and drinking in satiated rats (30).

To a great extent, experimental attention has been largely devoted to drug actions at dopamine D₂ receptors in relation to ingestive behaviour, e.g., (4, 11, 30, 32, 34). The relative neglect

of drug effects at the D₁ receptor is somewhat surprising, since dopamine release is thought to activate both D₁ and D₂ receptors simultaneously (23,39). Furthermore, dopamine itself has a 15 times greater affinity for the D₁ than for the D₂ receptor (35).

Nevertheless, some evidence for an anorectic effect of the selective D₁ receptor agonist (±)-SK&F 38393 (36) is available. We demonstrated a dose-related suppression of palatable food consumption in a 30-min test after SK&F 38393 (3.0–30 mg/kg) (13). Since the reduction in food intake occurred in the absence of gross behavioural stereotypy, we suggested that SK&F 38393 may act directly on feeding mechanisms. More recently, Martin-Iverson and Dourish reported that 5 mg/kg of (±)-SK&F 38393 significantly reduced consumption of laboratory chow in a 4-hr test using nondeprived rats (27). They also suggest that stimulation of D₁ receptors may have a direct influence on feeding behaviour. It is also noteworthy that, at least in part, *d*-amphetamine's anorectic effect may be mediated through D₁ receptor activation (13).

¹Requests for reprints should be addressed to S. J. Cooper

In the present series of experiments, we have investigated the effects of (\pm)-SK&F 38393 more extensively, using a number of feeding response paradigms. Its effects were evaluated not only on the consumption of a highly-palatable diet, but also on deprivation-induced feeding, and on operant responding for food under a FR8 schedule of reinforcement. The resolved enantiomers of SK&F 38393 were tested separately in mice. As a check on the generality of the SK&F 38393 effect, a further centrally-active selective D_1 receptor agonist, SK&F 75760 (35) was also tested in the palatable food paradigm. The peripheral dopamine D_1 receptor agonist, fenoldopam (7, 17, 26), was tested to control for possible peripheral changes having an indirect effect on food intake. Finally, the effects of (\pm)-SK&F 38393 on deprivation-induced water consumption in rats were examined, to assess the degree of behavioral specificity of the drug's anorectic effect.

METHOD

Animals

The subjects were 105 adult male hooded rats (General strain, 250–400 g) which were bred in the Psychology Department, University of Birmingham, and 28 adult male Swiss CD1 albino mice (27–40 g), purchased from Charles River, U K. They were housed singly, and were maintained on a 12-hr light/dark cycle with lights on at 8 a.m.

Drugs

Racemic SK&F 38393 (1-phenyl-7,8-dihydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine) hydrochloride and fenoldopam methane-sulphonate (SK&F 82526, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, methane-sulphonate) were generously supplied courtesy of Dr Jan Skidmore, Smith Kline & French Research Limited, Welwyn, Herts, U K. The resolved enantiomers, R(+)-SK&F 38393 hydrochloride (active) and S(–)-SK&F 38393 hydrochloride (inactive) were purchased from Research Biochemicals Inc. A sample of SK&F 75760 hydrobromide was kindly provided by Dr E. Nielsen of Novo Industri, Bagsvaerd, Denmark. The selective dopamine D_2 agonist, N-0437 (5,6,7,8-tetrahydro-6-propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol hydrochloride) was supplied by Nelson Research, Irvine, CA. The drugs were dissolved in distilled water and administered intraperitoneally. Drug doses are expressed in terms of the salts. Injection volumes were 1 ml/kg for rats and 5 ml/kg for mice.

Procedures

Palatable food consumption. Rats were adapted to eating a sweetened mash diet in daily 30-min sessions in their home cages. The mash consisted of 50 ml sweetened condensed milk, 150 ml ground rat maintenance diet No. 1 (Special Diet Services Ltd, Essex, U K) and 200 ml distilled water. The animals were given 40–50 g portions presented in a plastic shallow petri dish, and were considered adapted when baseline levels of intake reached asymptote, after 8–10 days of training. By the end of this period, the latency to begin eating the diet was minimal for all animals. The food was weighed before and after test sessions to 0.1 g accuracy, and care was taken to collect spillage. All tests took place between 12.00 and 16.00 hr during the light period.

Twenty naive rats were allocated to two equal groups. In one group, each animal was tested on five occasions after 0, 10, 30, 10 and 20 mg/kg of (\pm)-SK&F 38393 respectively. The order of injections was balanced across subjects, and at least 48 hr intervened between successive injections. For the first injection,

each dose level (including vehicle) was tested in two animals. Thereafter, animals were tested with other injections in order, maintaining two animals per dose level on each day of testing. In the second group, each animal was tested on two occasions after 0 or 50 mg/kg of SK&F 75760. Half of the animals were injected with vehicle first, and half with SK&F 75760. There was a 48-hr interval between the two injections. In a separate drug-combination study, 28 new rats were allocated to four equal treatment conditions: vehicle/vehicle, (\pm)-SK&F 38393 (100 mg/kg) + vehicle, vehicle + N-0437 (0.3 mg/kg), (\pm)-SK&F 38393 (100 mg/kg) + N-0437 (0.3 mg/kg). The D_1 agonist was injected 30 min before the feeding test, and the D_2 agonist was injected 15 min later. Doses of the two drugs were chosen to give modest reductions in food intake, and were given in combination to determine whether or not their effects are additive. To determine whether or not stimulation of peripheral D_1 receptors affects palatable food consumption, 30 new rats were divided into three equal groups. They were injected IP with fenoldopam at 30 or 10 mg/kg, or with vehicle respectively, 30 min before the feeding test. Fenoldopam poorly penetrates the blood-brain barrier, and at 20 mg/kg IP is devoid of central D_1 agonist activity in rats (17), at 10 mg/kg, however, there is evidence for slight central activity (17). Hence, if the anorectic effect of SK&F 38393 is centrally-mediated, we expected to find no effect of fenoldopam at 30 mg/kg, but possibly some reduction in intake at the higher dose.

Because of a limited supply of the compounds, the effects of the R(+)- and S(–)-enantiomers of SK&F 38393 on palatable food consumption were tested in adult mice. Individually-housed animals were adapted to eating the sweetened mash in daily 20-min test sessions. After 10 days, when levels of intake had reached asymptotic values, animals were injected with vehicle, 30, 100 or 300 mg/kg of either the R(+)-enantiomer ($n = 5$ per group) or the S(–)-enantiomer ($n = 7$ per group). Injections were made 20 min before the feeding test.

Deprivation-Induced Feeding

Eight rats were housed individually and were placed on a daily food-restriction schedule to maintain body weight at about 85% of the free-feeding weight. The animals were presented with approximately 20 g of powdered laboratory chow in glass jars each day as their sole source of food. Water was available *ad lib*. Food intake was measured by weighing before and after the first 30 min of food presentation, spillage being taken into account. When stable baseline levels of intake had been achieved (after 10 days), each rat was tested on four occasions, following injection of 30, 100 or 300 mg/kg of (\pm)-SK&F 38393, or its vehicle, respectively. The order of injection was counterbalanced across animals, and there were 48-hr intervals between successive injections.

Fixed-Ratio 8 Performance

Nine rats were similarly placed on a daily food-restriction schedule to maintain them at 85% of free-feeding body weight. They were trained to lever-press in commercial operant chambers (Campden Instruments) using conventional procedures. They were each given several one-hour habituation periods in the chamber, when each lever-press resulted in delivery of a single 45-mg sweetened pellet (Larkhall Laboratories, London). When the lever-pressing response had been shaped by an observer delivering food for successive approximations of the response, each animal was given 10 sessions (20 min duration) in which the reinforcement contingency was changed gradually from a CRF to an FR8 schedule of reinforcement. Each rat then had at least one week's training of lever-pressing under the FR8 schedule. Each animal




FIG 1 Palatable food consumption in rats was significantly reduced by 10 and 20 mg/kg of SK&F 38393 (left panel), and by 5 mg/kg SK&F 75760 (right panel) 30-min test. Results are shown in terms of mean \pm S.E.M. (N=10 per condition). Levels of significance in comparison with corresponding vehicle control: * p <0.05, ** p <0.01, *** p <0.005 (Dunnett's t -test).

was then tested on four occasions, following injection of vehicle, 3.0, 10.0 or 30.0 mg/kg (\pm)-SK&F 38393, respectively. The order of injection was counterbalanced across animals, and at least one drug-free day separated successive injections. During the 15-min test period, cumulative responses were recorded at 5-min intervals.

Deprivation-Induced Drinking

Ten naive rats were housed individually and were placed on a daily 22-hr water-deprivation schedule for 10 days, by which the levels of water consumption in the first 30 min of access to water (in the absence of food) had stabilised. Food was available ad lib in the home cage at all other times. Water intake (ml) in the 30-min period of access immediately following water deprivation was measured by reading levels in graduated cylinders, clipped to the outside of the cages, with the stainless-steel drinking spouts positioned inside. Each rat was tested on four occasions, following injection of 3.0, 10.0 or 30.0 mg/kg of (\pm)-SK&F 38393, or its vehicle, respectively. The order of injection was counterbalanced across animals, and at least 48 hr separated successful injections.

Statistical Analyses

The data were analysed using analysis of variance procedures. Means for individual drug dose conditions were compared with the corresponding vehicle condition using Dunnett's t -test.

RESULTS

Palatable Food Consumption

In rats, (\pm)-SK&F 38393 significantly reduced palatable food consumption, $F(4,36)=11.63$, $p<0.001$ (Fig. 1). Significant reductions occurred following the administration of 10 mg/kg (33.0% reduction) and 20 mg/kg (27.7%) of SK&F 38393. A greater effect occurred after injection of 5 mg/kg of SK&F 75760 (53%). When (\pm)-SK&F 38393 (10 mg/kg) was given in conjunction with the selective dopamine D_2 receptor agonist N-0437




FIG 2 Additive effects of 0.3 mg/kg of N-0437 (a selective D_2 receptor agonist) and 10 mg/kg of SK&F 38393 (a selective D_1 agonist) to reduce palatable food intake in rats. Results are shown in terms of mean \pm S.E.M. (N=7 per group). Levels of significance: see Fig. 1 legend.

(0.3 mg/kg), there was an additive effect to reduce food consumption (Fig. 2). In combination, the two compounds reduced intake by 72.6%, separately, SK&F 38393 reduced the level of feeding by 44.8% and N-0437 reduced it by 25.9%.

In the fenoldopam experiment, the control level of food intake was 19.9 ± 1.3 g in the 30-min test. At 3.0 mg/kg, fenoldopam had no significant effect on intake 17.3 ± 1.1 g. However, at 10 mg/kg fenoldopam, the level of food intake was 14.8 ± 1.1 g, which was significantly less ($p<0.05$, Dunnett's t -test) than the control value.

In mice, the active enantiomer R(+)-SK&F 38393 produced significant suppression of food consumption at each dose tested, $F(3,16)=17.5$, $p<0.001$. At 3.0 mg/kg, intake was reduced by 29.9%; at 30 mg/kg, food intake was potently suppressed by 85.5% (Fig. 3). In contrast, the inactive enantiomer S(-)-SK&F 38393 (3.0–30 mg/kg) had no significant overall effect on food intake, $F(3,24)=2.55$, N.S.

Deprivation-Induced Food Intake

In food-deprived rats, (\pm)-SK&F 38393 (3.0–30 mg/kg) produced a dose-dependent reduction in powdered food intake (Fig. 4). At 3.0 mg/kg, food intake was significantly reduced by 18.8%, at 10 mg/kg by 57.2%, while at 30 mg/kg feeding was almost completely suppressed.

Operant Responding for Food

Cumulative levels of lever pressing under a FR8 schedule of food reinforcement following administration of 3.0–30 mg/kg (\pm)-SK&F 38393 are shown in Fig. 5. The results indicate that levels of responding following injection of the vehicle remained relatively constant over the 15-min test. SK&F 38393 produced significant dose-related reductions in response rates, which were detectable within the first 5-min period, and in subsequent intervals. At 15 min, the reductions in response rates were 7.9% after 3.0 mg/kg (\pm)-SK&F 38393, 61.7% after 10 mg/kg and 91.7% after 30 mg/kg.

Deprivation-Induced Drinking

The results for the effects of (\pm)-SK&F 38393 on water




FIG 3 R(+)-SK&F 38393 produced a dose-related reduction in palatable food consumption in mice S(-)-SK&F 38393 had no significant effect on food intake Levels of significance see Fig 1 legend

consumption in water-deprived rats are shown in Table 1 There was a significant, dose-dependent reduction in water intake, $F(3,27) = 10.59, p < 0.001$ There was no effect on drinking at 3.0 mg/kg (13.4% reduction), and a significant reduction at 30.0 mg/kg (29.1%) Hence, (±)-SK&F 38393 was considerably less potent in its reduction of deprivation-induced drinking than in its reduction of deprivation-induced feeding

DISCUSSION

The present data confirm earlier findings that the selective dopamine D_1 agonist, SK&F 38393, significantly reduces food intake in the rat (13,27) They also extend previous observations and show that, first, (±)-SK&F 38393 is effective as an anorectic in food-deprived rats, producing a dose-dependent reduction in food intake over the dose range, 3.0–30 mg/kg Second, SK&F




FIG 4 SK&F 38393 produced significant, dose-related reductions in powdered chow consumption in food-deprived rats Results are shown in terms of mean ± S.E.M. (N=8 per group) Levels of significance see Fig 1 legend




FIG 5 SK&F 38393 dose-dependently reduced operant responding for food on a FR8 schedule of reinforcement in rats The results are shown as mean ± S.E.M. number of cumulative responses over a 15-min session (N=9 per condition) Responding was significantly attenuated at 10 mg/kg of SK&F 38393, and completely eliminated at 30 mg/kg Level of significance see Fig 1 legend

38393, in the form of the R(+)-enantiomer, was very effective in reducing palatable food consumption in mice Third, (±)-SK&F 38393 not only reduces food intake, but also reduces operant responding for food Dopamine D_1 receptor stimulation leads, therefore, to a reduction in appetitive responding in addition to its effects on the consummatory response of food ingestion

Several important pharmacological results emerged from the present series of experiments The stereoselectivity of the SK&F 38393 effect on food intake in mice satisfies a necessary criterion for dopamine D_1 receptor mediation (3,28) However, it must be noted that the comparison between the effects of the enantiomers of SK&F 38393 has yet to be made in rats We report for the first time that SK&F 75760, another selective D_1 agonist, significantly reduced palatable food consumption in rats The relevant D_1 receptors appear to be located centrally, rather than peripherally Fenoldopam (SK&F 82526) is a potent D_1 agonist which only poorly penetrates the blood-brain barrier (17) It is ineffective in small doses in drug discrimination studies in which rats have been trained with a SK&F 38393 cue (3,22) In our experiment, fenoldopam (3.0 mg/kg) had no effect on palatable food consumption, and therefore we conclude that stimulation of peripheral D_1 receptors does not underlie SK&F 38393's anorectic effect At the

TABLE 1
EFFECTS OF SK&F 38393 (3.0–30 mg/kg IP) ON WATER INTAKE IN 22-HR WATER-DEPRIVED RATS

	Dose (mg/kg)			
	0	3.0	10.0	30.0
Intake (ml)	17.9 ± 1.1	17.4 ± 0.6	15.5* ± 0.8	12.7† ± 1.0
% Reduction from control	—	2.8%	13.4%	29.1%

Results are shown as mean intake (ml) ± S.E.M. N=10 per group Levels of significance in comparison with vehicle control * $p < 0.05$, † $p < 0.01$, (Dunnett's *t*-test)

larger dose of 10 mg/kg, there may be penetration of fenoldopam into the brain (17), and this would explain the anorectic effect we detected. Lastly, some studies of D₁ and D₂ agonists indicate that they may have opposite effects (5,33). In the present experiments, however, the effects of SK&F 38393 and of the selective D₂ agonist, N-0437, were essentially additive. Thus, there was no evidence of antagonism between the two drugs. This is relevant to the anorectic potency of compounds like apomorphine, which stimulate both D₁ and D₂ receptors. Effects of mixed D₁/D₂ agonists to reduce food intake may depend on effects mediated by both receptor subtypes.

At a biochemical level, it is particularly interesting to note that SK&F 38393 affects neither brain dopamine metabolism (36), nor brain dopamine release (8,21). Its lack of effect stands in striking contrast to the marked changes brought about by selective D₂ agonists. Thus, SK&F 38393 furnishes an important example of a drug which acts via dopamine receptors to reduce food intake, in the absence of changes in dopamine metabolism or release. This dissociation may have implications for biochemical approaches to the study of brain dopamine and feeding (10, 20, 31, 37).

Reductions in food consumption produced by drug treatments can be problematic and difficult to interpret (12). Nevertheless, there are distinctive features to the pharmacological profile of SK&F 38393 which have a bearing on the question of the behavioural specificity of its anorectic effect. In contrast to D₂ agonists, SK&F 38393 does not induce emesis (36), so that one possible reason for a reduction in feeding is excluded. Also, in contrast to D₂ agonists, SK&F 38393 does not induce hyperactivity or behavioural stereotypy in either rats or mice (2, 14, 36, 38, 40). The reduction in food intake cannot readily be ascribed to the

interference of competing responses. In large doses, SK&F 38393 does induce excessive grooming in rats and mice (28,38). However, we have observed that, at 10 mg/kg, SK&F 38393 produced a reduction in food intake without significantly affecting grooming locomotor activity, or rearing (Cooper, Francis and Rusk, submitted for publication). There is evidence to suggest that the effects of SK&F 38393 on feeding responses are to some degree motivationally specific. Thus, deprivation-induced water intake was reduced by only 29%, at the large dose of 30.0 mg/kg of SK&F 38393. In contrast, operant responding for food and deprivation-induced food intake were strongly suppressed at this dose. Furthermore, SK&F 38393 has been reported to have no effect on female sexual behaviour in rats, in contrast to D₂ agonists (16). Nevertheless, the specificity of the effects of SK&F 38393 on feeding responses deserve further study, as do the mechanisms by which the drug achieves the suppressant effect on food intake.

In summary, the present series of experiments demonstrates that agonist activity at dopamine D₁ receptors leads to reductions in food consumption in both rats and mice. Operant responding for food was also reduced by (±)-SK&F 38393. There are good grounds for the view that SK&F 38393 achieves an anorectic effect which is not secondary to nonspecific motivation or response impairments. Finally, it appears possible that more familiar dopaminergic anorectic compounds, like apomorphine and *d*-amphetamine, may owe part of their effect on appetite to stimulation of central dopamine D₁ receptors.

ACKNOWLEDGEMENTS

We wish to thank John Francis and Adam Pitt for their help with the data collection, and drug companies for their gifts of drugs.

REFERENCES

1. Arneric, S. P., Roetker, A., Long, J. P. Potent anorectic-like effects of RDS-127(2-di-*n*-propylamino-4,7-dimethoxyindane) in the rat: a comparison with other dopamine-receptor agonists. *Neuropharmacology* 21: 885-890, 1982.
2. Arnt, J. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats. *Eur. J. Pharmacol.* 113: 79-88, 1985.
3. Arnt, J. The discriminative stimulus properties of the D-1 agonist SK&F 38393 and the D-2 agonist (±)-NPA are mediated by separate mechanisms. *Life Sci.* 42: 565-574, 1988.
4. Baptista, T., Parada, M., Hernandez, L. Pharmacological evidence that dopaminergic satiety systems function with D2 type receptors. *Pharmacol. Biochem. Behav.* 27: 399-405, 1987.
5. Barone, P., Bankiewicz, K. S., Corsini, G. U., Kopin, I. J., Chase, T. N. Dopaminergic mechanisms in hemiparkinsonian monkeys. *Neurology* 37: 1592-1595, 1987.
6. Barzaghi, R., Groppetti, A., Mantegazza, P., Muller, E. E. Reduction of food intake by apomorphine: a pimozide-sensitive effect. *J. Pharm. Pharmacol.* 25: 909-911, 1973.
7. Berkowitz, B. A., Ohlstein, E. H. Cardiovascular dopamine receptors: recent advances in agonists and antagonists of the DA₁-receptor. *J. Cardiovasc. Pharmacol.* 6: S559-S565, 1984.
8. Boyar, W. C., Altar, C. A. Modulation of *in vivo* dopamine release by D₂ but not D₁ receptor agonists and antagonists. *J. Neurochem.* 48: 824-831, 1987.
9. Carruba, M. O., Ricciardi, S., Muller, E. E., Mantegazza, P. Anorectic effect of lisuride and other ergot derivatives in the rat. *Eur. J. Pharmacol.* 64: 133-141, 1980.
10. Chance, W. T., Foley-Nelson, T., Nelson, J. L., Fischer, J. E. Neurotransmitter alterations associated with feeding and satiety. *Brain Res.* 416: 228-234, 1987.
11. Clifton, P. G., Rusk, I. M., Cooper, S. J. Stimulation and inhibition of food intake by the selective D₂ agonist, N-0437: A meal pattern analysis. *Pharmacol. Biochem. Behav.* 33: 21-26, 1989.
12. Cooper, S. J. Drugs and hormones: their effects on ingestion. In: Toates, F. M., Rowland, N. E., eds. *Feeding and drinking*. Amsterdam: Elsevier, 1987: 231-269.
13. Gilbert, D. B., Cooper, S. J. Analysis of dopamine D1 and D2 receptor involvement in *d*- and *l*-amphetamine-induced anorexia in rats. *Brain Res. Bull.* 15: 383-389, 1985.
14. Gower, A. J., Marriott, A. S. Pharmacological evidence for the subclassification of central dopamine receptors in the rat. *Br. J. Pharmacol.* 77: 185-194, 1982.
15. Greene, S. B., Matthews, D., Hollingsworth, E. M., Garbin, C. P. Behavioral effects of pergolide mesylate on food intake and body weight. *Pharmacol. Biochem. Behav.* 23: 161-167, 1985.
16. Grierson, J. P., James, M. D., Pearson, J. R., Wilson, C. A. The effect of selective D₁ and D₂ dopaminergic agents on sexual receptivity in the female rat. *Neuropharmacology* 27: 181-189, 1988.
17. Hahn, R. A., Wardell, J. R., Sarau, H. M., Ridley, P. T. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. *J. Pharmacol. Exp. Ther.* 223: 305-313, 1982.
18. Hawkins, M. F., Barkemeyer, C. A., Tulley, R. T. Synergistic effects of dopamine agonists and centrally administered neurotensin on feeding. *Pharmacol. Biochem. Behav.* 245: 1195-1201, 1986.
19. Heffner, T. G., Zigmond, M. J., Stricker, E. M. Effects of dopaminergic agonists and antagonists on feeding in intact and 6-hydroxydopamine-treated rats. *J. Pharmacol. Exp. Ther.* 201: 386-399, 1977.
20. Heffner, T. G., Hartman, J. A., Seiden, L. S. Feeding increases dopamine metabolism in the rat brain. *Science* 208: 1168-1170, 1980.
21. Imperato, A., Tanda, G., Frau, R., Di Chiara, G. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. *J. Pharmacol. Exp. Ther.* 245: 257-264, 1988.
22. Kamien, J. B., Woolverton, W. L. The D₁ dopamine agonist SK&F 38393 functions as a discriminative stimulus in rats. *Psychopharmacology (Berlin)* 87: 368-370, 1985.
23. Kelly, E., Nahorski, S. R. Endogenous dopamine functionally activates D-1 and D-2 receptors in striatum. *J. Neurochem.* 49: 115-120, 1987.
24. Lebowitz, S. F., Rossakis, C. Mapping study of brain dopamine- and

- epinephrine-sensitive sites which cause feeding suppression in the rat *Brain Res* 172 101–113, 1979
- 25 Lebowitz, S F , Rossakis, C Pharmacological characterization of perifornical hypothalamic dopamine receptors mediating feeding inhibition in the rat *Brain Res* 172 115–130, 1979
 - 26 Lokhandwala, M F , Steenberg, M L Evaluation of the effects of SKF 82526 and LY 171555 on presynaptic (DA₂) and postsynaptic (DA₁) dopamine receptors in rat kidney *J Auton Pharmacol* 4 272–277, 1984
 - 27 Martin-Iverson, M T , Dourish, C T Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats *Psychopharmacology* (Berlin) 96 370–374, 1988
 - 28 Molloy, A G , Waddington, J L Dopaminergic behaviour stereospecifically promoted by the D₁ agonist *R*-SK&F 38393 and selectively blocked by the D₁ antagonist SCH 23390 *Psychopharmacology* (Berlin) 82 400–410, 1984
 - 29 Muscat, R , Willner, P , Towell, A Apomorphine anorexia: a further pharmacological characterization *Eur J Pharmacol* 123 131, 1986
 - 30 Parada, M A , Hernandez, L , Hoebel, B G Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats *Pharmacol Biochem Behav* 30 917–923, 1988
 - 31 Radhakishun, F S , von Ree, J M , Westerink, B H C Scheduled eating increases dopamine release in the nucleus accumbens of food-deprived rats as assessed with on-line brain dialysis *Neurosci Lett* 85 351–356, 1988
 - 32 Rusk, I N , Cooper, S J Profile of the selective dopamine D-2 receptor agonist N-0437: its effects on palatability- and deprivation-induced feeding, and operant responding for food *Physiol Behav* 44 545–553, 1988
 - 33 Saller, C F , Salama, A I Dopamine receptor subtypes *in vivo*: biochemical evidence for functional interaction *Eur J Pharmacol* 109 297–300, 1985
 - 34 Schneider, L H , Gibbs, J , Smith, G P D-2 selective antagonists suppress sucrose sham feeding in the rat *Brain Res Bull* 17 605–611, 1986
 - 35 Seeman, P , Niznik, H B Dopamine D₁ receptor pharmacology: ISI atlas of science *Pharmacology* Philadelphia, PA: Institute for Scientific Information, 1988 161–170
 - 36 Setler, P E , Sarau, H M , Zirkle, C L , Saunders, H L The central effects of a novel dopamine agonist *Eur J Pharmacol* 50 419–430, 1978
 - 37 Simansky, K J , Bourbonais, K A , Smith, G P Food-related stimuli increase the ratio of 3,4-dihydroxyphenylacetic acid to dopamine in the hypothalamus *Pharmacol Biochem Behav* 23 253–258, 1985
 - 38 Starr, B S , Starr, M S Differential effects of dopamine D₁ and D₂ agonists and antagonists on velocity of movement, rearing and grooming in the mouse *Neuropharmacology* 25 455–563, 1986
 - 39 Stoof, J C , Kebabian, J W Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum *Nature* 294 366–368, 1981
 - 40 Vasse, M , Chagraoui, A , Protais, P Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors *Eur J Pharmacol* 148 221–229, 1988